John Librie joined the company in April 2013 as President and Chief Executive Officer. Mr. Librie brings over 30 years of experience in the biopharmaceutical industry, including extensive executive level experience. Prior to joining ONY, Mr. Librie was General Manager and Chief Executive Officer at Shore Therapeutics, a privately held company.
Mr. Librie’s experience includes Acorda Therapeutics, where he held the position of Senior Vice President, Sales and Marketing and BTG Pharmaceuticals where he was a Vice President. Earlier in his career, Mr. Librie was with Genentech during the initial days of commercialization.